NASDAQ:ABEO Abeona Therapeutics - ABEO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Abeona Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. $2.39 -0.15 (-5.91%) (As of 03/17/2023 06:55 PM ET) Add Compare Share Share Today's Range$2.35▼$2.5550-Day Range$2.25▼$3.2752-Week Range$2.19▼$9.35Volume325,700 shsAverage Volume207,881 shsMarket Capitalization$41.06 millionP/E RatioN/ADividend YieldN/APrice Target$22.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Abeona Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,573.6% Upside$40.00 Price TargetShort InterestHealthy2.78% of Float Sold ShortDividend StrengthN/ASustainability-1.03Upright™ Environmental ScoreNews Sentiment0.41Based on 6 Articles This WeekInsider TradingSelling Shares$2,385 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector362nd out of 983 stocksPharmaceutical Preparations Industry156th out of 480 stocks 3.5 Analyst's Opinion Consensus RatingAbeona Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $40.00, Abeona Therapeutics has a forecasted upside of 1,573.6% from its current price of $2.39.Amount of Analyst CoverageAbeona Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.78% of the float of Abeona Therapeutics has been sold short.Short Interest Ratio / Days to CoverAbeona Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Abeona Therapeutics has recently increased by 6.70%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAbeona Therapeutics does not currently pay a dividend.Dividend GrowthAbeona Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAbeona Therapeutics has received a 69.10% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases ", "Clinical research services for genetic diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Abeona Therapeutics is -1.03. Previous Next 2.5 News and Social Media Coverage News SentimentAbeona Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Abeona Therapeutics this week, compared to 1 article on an average week.Search Interest9 people have searched for ABEO on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Abeona Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,385.00 in company stock.Percentage Held by InsidersOnly 2.40% of the stock of Abeona Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 37.69% of the stock of Abeona Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Abeona Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Abeona Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbeona Therapeutics has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Abeona Therapeutics (NASDAQ:ABEO) StockAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Read More Receive ABEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ABEO Stock News HeadlinesMarch 18, 2023 | americanbankingnews.comAbeona Therapeutics Inc (NASDAQ:ABEO) Short Interest UpdateMarch 17, 2023 | americanbankingnews.comAbeona Therapeutics (NASDAQ:ABEO) Receives New Coverage from Analysts at StockNews.comMarch 20, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 16, 2023 | finance.yahoo.comAbeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 MeetingMarch 15, 2023 | marketwatch.comPolymer Drug Conjugates Market Application, Product, Sales and Forecast 2023-2028March 14, 2023 | finance.yahoo.comAbeona Therapeutics Announces Update on AAV Ophthalmology ProgramMarch 10, 2023 | marketwatch.comGlobal Alpha 1 Antitrypsin Deficiency Treatment Market 2023 Revenue, Competitive Dynamics, Advancement, and Forecast to 2030 By VMReportsMarch 3, 2023 | marketwatch.comAlpha-1 Antitrypsin Drugs New Investments Expected to Boost the Demand by 2028March 20, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. February 23, 2023 | marketwatch.com2023 Latest Genetic Modification Therapies Market Research: Pricing Strategy and Analysis for PRODUCT TYPE by 2028February 20, 2023 | finance.yahoo.comGenetic Chronic Obstructive Pulmonary Disease (COPD) Market to Surpass US$ 720.5 Million by 2030, Says Coherent Market Insights (CMI)February 18, 2023 | marketwatch.comAlpha-1 Antitrypsin Drugs Market by Top Manufacturers, Growing Demand and Supply 2023-2028February 14, 2023 | marketwatch.comPolymer Drug Conjugates Market Massive Growth Strikes Due To Technological Innovation During 2023-2028February 14, 2023 | marketwatch.comMucopolysaccharidosis Therapeutics Market 2023 Assessed to See Remarkable Growth till 2028 | Says Absolute Reports ExpertsFebruary 7, 2023 | marketwatch.comAlpha 1 Antitrypsin Deficiency Treatment Market Latest Research Report with Growth Projection and top Industry Analysis 2023-2028January 26, 2023 | marketwatch.comAlpha-1 Antitrypsin Drugs Market Provides an In-Depth Insight of Trends and Landscape Outlook 2023-2028January 20, 2023 | marketwatch.comPolymer Drug Conjugates Market 2023 : Business Scenario, Corporate Profiles, Size and Dynamic Innovation by 2028January 3, 2023 | finance.yahoo.comCNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of DirectorsNovember 15, 2022 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (ASND) and Abeona Therapeutics (ABEO)November 14, 2022 | finanznachrichten.deAbeona Therapeutics Inc.: Abeona Therapeutics Reports Third Quarter 2022 Financial ResultsNovember 14, 2022 | finance.yahoo.comAbeona Therapeutics Reports Third Quarter 2022 Financial ResultsNovember 8, 2022 | finance.yahoo.comCantor Bullish On Abeona Saying Recent Trial Data 'Best Case Scenario'November 4, 2022 | finance.yahoo.comAbeona Therapeutics Touts Positive Data From Pivotal EB-101 Study In Blistering Skin DisorderNovember 3, 2022 | finance.yahoo.comAbeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101November 3, 2022 | finance.yahoo.comAbeona Therapeutics Announces $35 Million Private Placement FinancingOctober 19, 2022 | finance.yahoo.comAbeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)October 7, 2022 | msn.comHow Is The Market Feeling About Abeona Therapeutics?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ABEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ABEO Company Calendar Last Earnings11/15/2021Today3/20/2023Next Earnings (Estimated)3/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABEO Previous SymbolOTCMKTS:ACCP CUSIPN/A CIK318306 Webwww.abeonatherapeutics.com Phone214-665-9495Fax214-905-5101EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$40.00 High Stock Price Forecast$40.00 Low Stock Price Forecast$40.00 Forecasted Upside/Downside+820.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($18.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-84,940,000.00 Net MarginsN/A Pretax Margin-1,961.64% Return on Equity-157.61% Return on Assets-85.45% Debt Debt-to-Equity RatioN/A Current Ratio2.02 Quick Ratio2.02 Sales & Book Value Annual Sales$3 million Price / Sales13.69 Cash FlowN/A Price / Cash FlowN/A Book Value$8.73 per share Price / Book0.27Miscellaneous Outstanding Shares17,180,000Free Float16,764,000Market Cap$41.06 million OptionableOptionable Beta1.20 Key ExecutivesMr. Steven H. Rouhandeh (Age 61)Exec. Chairman Dr. Timothy J. Miller (Age 46)Pres, Chief Scientific Officer & Director Mr. Jeffrey Blaine Davis (Age 55)Chief Operating Officer Mr. Carsten Thiel (Age 54)Chief Exec. Officer Mr. Stephen B. Thompson (Age 64)Sr. VP of Fin. and Admin., Chief Accounting Officer, Sec. & Treasurer Key CompetitorsMagenta TherapeuticsNASDAQ:MGTABeyondSpringNASDAQ:BYSIASLAN PharmaceuticalsNASDAQ:ASLNIO BiotechNASDAQ:IOBTHookipa PharmaNASDAQ:HOOKView All CompetitorsInsiders & InstitutionsMichael AmorosoSold 1,002 sharesTotal: $2,384.76 ($2.38/share)AIGH Capital Management LLCBought 511,530 shares on 2/16/2023Ownership: 3.796%Armistice Capital LLCBought 1,106,000 shares on 2/15/2023Ownership: 6.438%Nantahala Capital Management LLCBought 272,731 shares on 2/15/2023Ownership: 1.587%Millennium Management LLCBought 147,779 shares on 2/15/2023Ownership: 0.860%View All Insider TransactionsView All Institutional Transactions ABEO Stock - Frequently Asked Questions Should I buy or sell Abeona Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ABEO shares. View ABEO analyst ratings or view top-rated stocks. What is Abeona Therapeutics' stock price forecast for 2023? 2 analysts have issued 1-year price objectives for Abeona Therapeutics' stock. Their ABEO share price forecasts range from $40.00 to $40.00. On average, they expect the company's share price to reach $40.00 in the next year. This suggests a possible upside of 1,573.6% from the stock's current price. View analysts price targets for ABEO or view top-rated stocks among Wall Street analysts. How have ABEO shares performed in 2023? Abeona Therapeutics' stock was trading at $3.08 at the start of the year. Since then, ABEO stock has decreased by 22.4% and is now trading at $2.39. View the best growth stocks for 2023 here. Are investors shorting Abeona Therapeutics? Abeona Therapeutics saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 460,500 shares, an increase of 6.7% from the February 13th total of 431,600 shares. Based on an average daily volume of 244,900 shares, the short-interest ratio is presently 1.9 days. Currently, 2.8% of the company's shares are short sold. View Abeona Therapeutics' Short Interest. When is Abeona Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023. View our ABEO earnings forecast. How were Abeona Therapeutics' earnings last quarter? Abeona Therapeutics Inc (NASDAQ:ABEO) issued its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($4.00) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($4.00). When did Abeona Therapeutics' stock split? Abeona Therapeutics shares reverse split on the morning of Tuesday, July 5th 2022. The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Abeona Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Abeona Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Energy Transfer (ET), Sorrento Therapeutics (SRNE), Micron Technology (MU), TherapeuticsMD (TXMD), VBI Vaccines (VBIV) and Advanced Micro Devices (AMD). What is Abeona Therapeutics' stock symbol? Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO." Who are Abeona Therapeutics' major shareholders? Abeona Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (6.70%), Armistice Capital LLC (6.44%), EcoR1 Capital LLC (6.33%), AIGH Capital Management LLC (3.80%), Nantahala Capital Management LLC (1.59%) and Barclays PLC (1.08%). Insiders that own company stock include Brendan M O'malley, Edward Carr, Joseph Walter Vazzano, Mark Alvino, Michael Amoroso, Paul Elliot Mann, Sco Capital Partners Llc and Todd Wider. View institutional ownership trends. How do I buy shares of Abeona Therapeutics? Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Abeona Therapeutics' stock price today? One share of ABEO stock can currently be purchased for approximately $2.39. How much money does Abeona Therapeutics make? Abeona Therapeutics (NASDAQ:ABEO) has a market capitalization of $41.06 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-84,940,000.00 in net income (profit) each year or ($18.31) on an earnings per share basis. How can I contact Abeona Therapeutics? Abeona Therapeutics' mailing address is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. The official website for the company is www.abeonatherapeutics.com. The biopharmaceutical company can be reached via phone at 214-665-9495, via email at ir@abeonatherapeutics.com, or via fax at 214-905-5101. This page (NASDAQ:ABEO) was last updated on 3/20/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.